A small but steady stream of medicines has moved from prescription-only (POM) to pharmacy-only (P) supply in the UK over the last decade. Each reclassification is approved by the Medicines and Healthcare products Regulatory Agency following a formal application, usually from the license-holder, backed by safety data from real-world use.
Most of the switches are not headline-grabbing. They are modest step-changes that let a pharmacist supply something that previously required a GP appointment, usually for a self-diagnosable and self-manageable condition. But collectively they have changed what a UK community pharmacy is allowed to do.
The medicines in scope
| Medicine | Indication | Typical switch era | What changed |
|---|---|---|---|
| Omeprazole 10mg/20mg | Reflux, heartburn | Long-established P since mid-2000s; 20mg extended more recently | Now widely available in supermarkets and pharmacies as Pyrocalm and own-brand |
| Pantoprazole 20mg | Reflux | Pharmacy-only as Control and own-brand | Alongside omeprazole as a P-class PPI option |
| Famotidine 10mg | Heartburn | Long P; relaunched in pharmacy after ranitidine withdrawal | Filled the gap created by the 2019/2020 ranitidine withdrawal |
| Fexofenadine 120mg | Hay fever, allergy | Reclassified to P in 2020 | First non-sedating prescription-strength antihistamine available OTC |
| Tamsulosin 400mcg | Benign prostatic enlargement (BPE) | Reclassified to P in 2010 | Pharmacy supply under an assessment pathway for men with moderate urinary symptoms |
| Sildenafil 50mg | Erectile dysfunction | Reclassified as Viagra Connect in 2018 | First OTC phosphodiesterase inhibitor in the UK; pharmacist-led assessment |
| Chloramphenicol eye drops 0.5% | Acute bacterial conjunctivitis | Reclassified 2005 | Same-day supply without a prescription |
| Nasal fluticasone | Hay fever, allergic rhinitis | Long-established P | Available as Flixonase and generics |
| Orlistat 60mg (alli) | Weight management (BMI ≥28) | Reclassified 2009 | Pharmacy supply with lifestyle counselling |
The switches cluster in three therapy areas: gastro-reflux, respiratory allergy, and male-specific urogenital conditions. Each has a well-characterised safety profile when used for short periods without medical supervision, which is what makes the reclassification case defensible to the regulator.
Why the switches matter
Reclassification has three practical effects. First, it shifts workload away from general practice — a patient with mild-to-moderate heartburn no longer needs a GP appointment to access a PPI. Second, it lets the pharmacy charge a market price rather than operating under the NHS fixed prescription fee. Third, it creates a structured clinical conversation at the point of supply, because every P medicine requires a pharmacist assessment before sale.
The tamsulosin switch is the most interesting example. The medicine is used to treat benign prostatic enlargement, a condition that is common, typically self-identifiable, but sits at the edge of what would traditionally be considered self-diagnosable. The MHRA approved the switch on the condition that supply was accompanied by a validated International Prostate Symptom Score assessment and a clear referral route to a GP if red flags appeared.
The ones that didn't switch
Not every application succeeds. Oral proton pump inhibitors at higher strengths (omeprazole 40mg, esomeprazole) remain prescription-only. Statins, despite repeated industry interest, are still POM in the UK. Oral sumatriptan for migraine sits in a middle zone — licensed P use exists under Imigran Recovery but remains tightly controlled.
Switches that are not approved tend to share one of three concerns: the diagnosis is not reliably self-made (migraine versus thunderclap headache), the medicine interacts meaningfully with common comedication (oral anticoagulants), or long-term use without review carries population-level harm that pharmacy supply cannot easily gate (high-dose PPIs).
What a pharmacist assessment looks like
The assessment varies by medicine but typically checks four things: confirmation of the indication; review of any red flags that would warrant GP review; check of contraindications including drug interactions; and a record of the supply. For tamsulosin that means an IPSS form. For sildenafil it means a cardiovascular risk checklist. For orlistat it means a BMI and dietary-advice conversation.
This is time the pharmacy is not paid for directly — the income comes from the medicine sale — which explains why some pharmacies stock the medicines but only the larger, better-resourced sites actively promote the P-class assessment services.
What may switch next
The MHRA has publicly consulted on possible future reclassifications including simvastatin, naproxen at higher strengths, and oral contraceptives. A desogestrel progestogen-only pill was reclassified to P in 2021 under the Hana and Lovima brands. The direction of travel is clear: medicines that have long real-world safety data and a self-manageable indication are candidates; medicines that need diagnostic imaging, monitoring bloods or structured follow-up are not.
Where to get advice
For specific product availability and pharmacist assessment hours, PharmSee's pharmacy finder shows branch locations and opening times by postcode. The NHS.uk medicines library documents indications, side-effects and cautions for each of the medicines listed above.
Caveats
Reclassification status is current as of April 2026 and specific product brands may not be stocked by every pharmacy. Not all P medicines are sold at the same price across the UK — pricing is set by the retailer, not the NHS. Patients with ongoing symptoms that require any of these medicines for more than a short course should be reviewed by a GP.